文献速递围术期管理与 ERAS

新辅助免疫化疗后非小细胞肺癌微创手术可行性与术前预测难度的大样本多中心研究

Minimally invasive surgery could be attempted with preoperatively predictable difficulty for non-small cell lung cancer after neoadjuvant immunochemotherapy: A large multicenter study.
PubMed 文献 · Surgery · 2025-05-31

该多中心回顾性研究纳入2019至2024年12家机构571例IIA-IIIB期(除外T4N2)接受新辅助免疫化疗的非小细胞肺癌患者,比较微创手术与开胸手术的围术期结局与肿瘤疗效。倾向性评分匹配后每组240例,微创手术减少术中出血、缩短胸管留置和住院时间、减轻术后疼痛并降低并发症,中转率15.8%且中转后围术期结局与开胸相似。回归识别鳞癌、诱导前N分期晚、术前肿瘤>5 cm、术前分期晚和扩大切除为独立中转风险因素,列线图预测性能良好(AUC=0.804),两组无事件生存和总生存相当。

要点

  • 新辅助免疫化疗后微创手术围术期结局优于开胸,中转率15.8%可接受。
  • 鳞癌、诱导前N分期晚、肿瘤>5 cm、分期晚和扩大切除为独立中转风险因素。
  • 列线图可术前预测中转概率(AUC=0.804),辅助手术决策。

核心结论

  • 微创手术在新辅助免疫化疗后的非小细胞肺癌中实现改善的围术期结局和与开胸相似的肿瘤疗效。
  • 微创手术中转率可接受,且中转后围术期结局与开胸相当,可通过预测模型有效预估。

研究设计与样本

  • 多中心回顾性研究,纳入2019至2024年12家机构初始IIA-IIIB期(除外T4N2)接受新辅助免疫化疗后行微创手术或开胸的非小细胞肺癌患者。
  • 共纳入571例,倾向性评分匹配后每组240例;微创手术难度以中转开胸定义。

主要发现

  • 与开胸相比,微创手术减少术中出血、缩短术后胸管留置时间和住院时间、减轻术后疼痛并降低术后并发症。
  • 微创手术中转率为15.8%,中转微创手术的围术期结局与开胸手术相似。
  • 术者经验积累可降低微创手术中转率并缩短手术时间。
  • 逻辑回归识别鳞状细胞癌、诱导前N分期晚、术前肿瘤大小>5 cm、术前分期晚和扩大切除为中转的独立风险因素。
  • 列线图预测中转概率性能良好(AUC=0.804)且具有临床实用性;微创手术与开胸的无事件生存和总生存相当。

关键数值与推荐

  • 微创手术中转率15.8%。
  • 预测列线图的AUC值为0.804。
  • 中转的独立风险因素包括鳞状细胞癌、诱导前N分期晚、术前肿瘤大小>5 cm、术前分期晚和扩大切除。

临床怎么用

  • 对新辅助免疫化疗后的非小细胞肺癌患者,可尝试微创手术,预期围术期结局改善且肿瘤疗效不劣于开胸。
  • 术前可使用基于鳞癌、诱导前N分期、肿瘤大小、术前分期和扩大切除的列线图预测中转概率,辅助手术规划。
  • 术中如遇困难及时中转开胸,中转后围术期结局与开胸相当,不应因担心中转而放弃微创尝试。

局限性

  • 回顾性研究设计。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant immunochemotherapy has revolutionized the treatment of non-small cell lung cancer. However, it presents significant surgical challenges, leading to controversy over the feasibility and safety of minimally invasive surgery. This study aims to assess the adequacy of minimally invasive surgery and preoperatively predict its difficulty for non-small cell lung cancer after neoadjuvant immunochemotherapy. METHODS: Initial stage IIA-IIIB (excluding stage T4N2) non-small cell lung cancer patients with neoadjuvant immunochemotherapy undergoing minimally invasive surgery or open thoracotomy at 12 institutions between 2019 and 2024 were retrospectively reviewed. Difficult minimally invasive surgery was defined by conversion to thoracotomy. Propensity score matching was applied to balance baseline characteristics. RESULTS: Of the 571 cases included, propensity score matching led to 240 patients per group. Minimally invasive surgery decreased intraoperative bleeding, shortened postoperative chest tube duration and hospitalization, ameliorated postoperative pain, and reduced postoperative complications compared to open thoracotomy. Moreover, minimally invasive surgery had an acceptable conversion rate of 15.8%, and notably, converted minimally invasive surgery achieved similar perioperative outcomes to open thoracotomy. Accumulated surgeons' experiences reduced minimally invasive surgery conversion rates and shortened surgical durations. Additionally, logistic regression identified squamous cell carcinoma, advanced preinduction N stage, preoperative tumor size >5 cm, advanced preoperative stage, and extended resection as independent risk factors for conversion. A nomogram was further established with good performance (area under curve value = 0.804) and clinical utility to predict conversion probability preoperatively. Finally, minimally invasive surgery and open thoracotomy achieved comparable event-free survival and overall survival profiles. CONCLUSIONS: Minimally invasive surgery achieved improved perioperative outcomes and similar oncologic efficacies to open thoracotomy. Moreover, minimally invasive surgery had an acceptable conversion rate, which would not compromise perioperative outcomes compared with open thoracotomy and could be effectively forecasted by a prediction model.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Pan H, Chen H, Kong W, et al. Minimally invasive surgery could be attempted with preoperatively predictable difficulty for non-small cell lung cancer after neoadjuvant immunochemotherapy: A large multicenter study. Surgery. 2025. PMID: 40450812. doi:10.1016/j.surg.2025.109458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。